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ABSTRACT
Proton pump inhibitor (PPI) is the strongest inhibitor to gastric acid secretion. PPI is effective in all gastric 
acid disorders, such as: peptic ulcer, gastroesofageal reflux disease, non steroid anti inflammatory drugs (NSAIDs) 
gastropathy, and Zollinger-Ellison syndrome. Several studies comparing one PPI to another. Although some 
differences have been reported, there are small differences with unclear clinical importance.
PPI has side effects that may be related to diarrhea due to Clostridium difficile, pneumonia, hip fracture, 
vitamin B12 deficiency, and IgE mediated allergic reaction. Several studies revealed strong association but have 
limitation in design and sampel size. PPI therapy should be according to indication, dose, and appropriate period. 
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ABSTRAK
Penghambat pompa proton (PPP) adalah inhibitor paling kuat terhadap sekresi asam lambung. PPP 
efektif untuk terapi semua gangguan asam lambung termasuk ulkus peptikum, penyakit gastroesofageal reflux, 
gastropati karena obat anti inflamasi non steroid (OAINS), dan sindrom Zollinger-Ellison. Beberapa penelitian 
membandingkan beragam PPP satu dengan yang lainnya. Walaupun dilaporkan ada beberapa perbedaan, 
namun besaran perbedaannya kecil dan tidak jelas kepentingan klinisnya.
PPP kemungkinan berkaitan dengan efek samping diare karena Clostridium difficile, pneumonia, fraktur 
panggul, defisiensi vitamin B12, dan reaksi alergi yang dimediasi IgE. Beberapa penelitian menunjukkan 
hubungan yang kuat namun memiliki keterbatasan desain dan besaran sampel. Terapi PPP harus sesuai dengan 
indikasi, dosis, dan jangka waktu yang tepat. 
Kata kunci: penghambat pompa proton, gangguan asam lambung, indikasi, dosis, jangka waktu
INTRODUCTION
The invention of proton pump inhibitor (PPI) 
in the end of 1980 optimalize treatment of gastric 
acid disorder. Clinicians should evaluate the role of 
gastric acid in extraesofageal manifestation from 
gastroesofageal reflux disease (GERD), including 
non-cardiac chest pain and tracheopulmonar disease.1
Chronic treatment using PPI is indicated to several 
conditions, such as long duration therapy of GERD 
and supporting therapy in preventing peptic ulcer 
which is induced by nonsteroidal anti inflammatory 
drug (NSAID).2,3 In year 2008, there was 113,4 
billion prescription of PPI with sales of 13.9 trillion 
US dollars.4 PPI is considered safe, with rare serious 
side effects. However, recently it has been observed 
that PPI treatment is associated with increased 
fracture risk although results of clinical studies are 
still controversial.5 PPI strongly inhibits gastric acid 
secretion, increases intra gaster pH, and decrease the 
concentration of hidrogen ion several hundreds or 
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thousands fold. As a consequence, PPI has the potency 
to influence essential micronutrients, including vitamin 
C, vitamin B12, and iron when it passes the gaster, 
disturbs their activity in the gastric lumen and also 
the bioavailability.6 
This review article provides the pharmacologic 
appearance and clinical efficacy of PPI in various acid-
related disorders and issues about the comparison of 
these drugs, long term effects, side effects, and drug 
interaction.
PHYSIOLOGY OF GASTRIC ACID SECRETION
Gaster in normal individual consist of one million 
parietal cells which secrete 0.16 million of gastric 
acid (hydrochloric acid or HCl) in gastric lumen in 
response to 3 important physiologic stimuli, such as 
acetylcholine, histamine, and gastrin.7
Histamine release by gastrin from enterochrommafin-
like cells (ECL) seem to be the main physiologic 
mechanism in which gastrin stimulate gastric secretion, 
although parietal cells also has gastrin receptors. 
ECL cells integrate stimuli message from cholinergic 
nervous and inhibition from local somatostatin.7
Acetylcholine is a main neurocrine transmiter 
released by postganglionic vagal nerve and stimulate 
generation of hydrogen ion directly through M3 
muscarinic parietal cell receptors. Histamine is primary 
paracrine transmiter which is bound to H2 specific 
receptor in basolateral membrane parietal cells, while 
gastrin which is secreted in antral G cell combines 
primary endocrine pathway. Gastrin stimulate 
generation of hydrogen ion directly and indirectly 
by stimulating histamine secretion from ECL cells in 
proximal area parietal cells.7
Although the interaction of these three pathways 
is coordinated to stimulate or inhibit generation of 
hydrogen ion, histamine tends to represent dominant 
route as gastrin stimulate acid secretion by inhibiting 
histamine release from ECL cells. Because the 
dominancy of this pathway, blockage of H-2 receptors 
becomes the main way of inhibiting acid secretion in 
mid 1970s.7
As long as not stimulated (base phase), percentage 
of parietal cells volume comprises of tubulovesicle 
which is a long tube with smooth membrane surface 
and from secretory canaliculi an invagination area 
in apical membrane. During food stimulation, the 
amount of this tubulovesicles decreases and transforms 
into microvili around secretory canaliculi which 
cause expansion of the parietal cells' surface area in 
preparation to actively transport hydrogen ion in large 
amount against an ion gradient 3,000,000:1. Hydrogen 
ion is actively secreted in the exchange of potassium 
ion with the help of H-K-ATPase which is also known 
as proton pump located in the apical surface of parietal 
cells. H-K-ATPase plays role in the last pathway in 
which HCl is secreted to the gastric lumen, where HCl 
acts to hydrolize food protein and maintains sterile 
environment.7
PHARMACOLOGICAL ASPECTS OF PROTON 
PUMP INHIBITOR
Introduction of H-K-ATP-ase as the end phase of 
acid secretion, influence the development of PPI which 
is targeted to decrease this enzyme. All PPI has usual 
structural motive but with variable substitution. PPI in 
piridin has weak proton with pKa 4.0 for omeprazole/
esomeprazole and lansoprazole/dexlansoprazole, about 
3.9 for pantoprazole and about 5.0 for rabeprazole. As 
a result, they accumulate specifically and selectively in 
secretory canaliculi, a very acidic space in parietal cell. 
In that space, PPI convert acid catalyst into reactive 
species, thiophillic sulphonamode, a permanent cation.7 
The conversion rate varies in its composition 
and proportional contract to pKa benzimidazole 
rabeprazole > omeprazole/esomeprazol = lansoprazole/ 
dexlansoprazole > pantoprazole.7 Reactive species 
interact with outer membrane of H-K-ATPase which 
face secretory lumen of parietal cells, producing 
formation of disulphide bond and cystein 813 which 
is located in alpha subunit enzyme. Inhibition of this 
covalent enzyme by thiophillic sulphonamide produce 
specific disruption which is long-lasting in gastric acid 
secretion.7 
PPI is the strongest inhibitor of gastric acid 
secretion.1 PPI acts most effective when parietal cell 
is stimulated to secrete acid after meal, which give 
clinical implication on administration time. Due 
to the number of H-K-ATPase present in parietal 
cells is higher after long fasting, PPI has to be given 
before the first meal in a day. In most people, once 
daily PPI is enough to produce acid inhibition, and 
second dose sometimes need to be given before 
dinner.1 PPI may not be given in combination with 
H2-antagonist, prostaglandin, and other antisecretory 
because the decrease effect of acid inhibition if given 
simultaneously.1 H2 antagonist can be used with PPI, 
but with enough interval timing (the exact interval time 
cannot be defined yet). As an example, H2 antagonist 
can be given before sleep or all night long in patients 
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with nocturnal recurrence, including burning sensation 
in the chest after consuming PPI in the morning.1
During meal, all parietal cells and proton pumps 
are active. Considering that PPI only inhibit enzymes 
which are activated in canaliculi membrane, the 
decrease of gastric acid after initial dose is not yet 
optimal. After second and third dose, inhibition of 
gastric acid secretion then occur.1
The dose of once daily PPI inhibit acid secretion 
upto maximum around 66% after five days. Several 
use of PPI are not adequate to inhibit acid, therefore 
do not produce consistent and satisfyinv clinical 
response (different with H2 antagonist which has 
faster onset of action).1 Due to the delay in optimal 
acid inhibition, initial use with twice daily dose (for 
the first 2-3 days) may be helpful to obtain faster 
gastric acid inhibition. Additionally in the later onset, 
because sulphonamide from PPI binds covalently to 
H-K-ATPase, the recovery of acid secretion is delayed, 
depending on the enzyme turnover and biological 
reversibility of disulphide bond. Maximum capacity of 
gastric secretion may not come back after 24-48 hours 
of PPI cessation. Rebound of acid hypersecretion may 
occur after discontinuation of PPI.1
THE ROLE OF PPI IN MANAGEMENT OF ACID-
RELATED DISORDERS
Peptic Ulcer Disease
PPI heals gastroduodenal ulcers faster than H2 
receptor antagonist. A meta-analysis comparing the 
recovery of duodenal ulcer revealed that omeprazole 
20 mg daily in the morning for 4 weeks was more 
superior than ranitidine 300 mg and cimetidine 800 mg 
given at night before bed. Other similar meta-analysis 
showed that lansoprazole 30 mg every morning cured 
more ulcers significantly than ranitidine 300 mg and 
famotidine 40 mg before bed.8 The peak cure rate was 
60-85% for 2 and 4 weeks regimen of lansoprazole, 
while it was only 40-75% for H2 antagonist. 
Pantoprazole and rabeprazole was also more superior 
in accelerating ulcer healimg than H2 antagonist. 
Optimal duration of use for PPI should be 4-8 weeks 
in duodenal ulcers and acute gastritis.8
Eradication of Helicobacter pylori
PPI plays its role in H. pylori eradication with 
antibiotics regimen. Antibiotics combination in 
eradication of H. pylori has 2-3 possible options. Triple 
therapy consists of Clarithromycin 500 mg twice daily, 
Amoxicillin 1 g twice daily, and PPI one capsule twice 
daily for 10-14 days. Fourth daily therapy consists of 
metronidazole, tetracycline, bismuth, and PPI in case of 
H. pylori resistance against clarithromycin or patients 
allergic to amoxicillin. Twice daily therapy including 
PPI and antibiotics for 5 days followed by PPI and 
two different antibiotics for 5 days showed 90% rate 
of eradication.8
Treatment and Prevention of Gastroduodenal Ulcers 
Associated with Non-Steroid Anti Inflammatory 
Drug 
Some studies showed that PPI was more effective 
than H2 antagonist to treat gastroduodenal ulcers 
related to non-steroidal antiinflammatory drug 
(NSAID) when NSAID should not be terminated. PPI 
was also more effective than misoprostol in primary 
prevention against NSAID-related ulcers.3
Risk factors of having gastrointestinal complications 
related to NSAID include previous gastrointestinal 
events (particularly those with complications), age, and 
concomittant use of anticoagulants, corticosteroids, 
other NSAIDs including low dose aspirin, high 
dose NSAID, and other chronic conditions such as 
cardiovascular disease. Low dose aspirin is associated 
with the risk of gastrointestinal complication. H. 
pylori infection increases the risk of NSAID-related 
gastrointestinal complications. There is benefit of 
using H. pylori infection test and initiating eradication 
when it is positive in patients who need long term 
NSAID treatment. It depends on the underlying risk 
in each patients whether they need concomittant use of 
gastroprotective drugs after eradication or not.3
PPI may significantly reduce gastric and duodenal 
ulcers and their complications in patients treated with 
NSAID or COX-2 inhibitors.3 COX-2 inhibitors are 
associated with the significantly lower incidence of 
gastric and duodenal ulcers as compared to traditional 
NSAIDs. This benefit vanishes as the patients also 
use low dose aspirin. The application of this drug is 
also reduced due to its association with myocardial 
infarction and other thrombotic cardiovascular events. 
The lowest dose of celecoxib is used to minimize the 
risk of cardiovascular events.3
Patients who need NSAID therapy with high 
risk (such as bleeding of previous ulcers or multiple 
gastrointestinal risk) should receive alternative 
treatments or, if anti inflammatory treatment is absolutely 
necessary, COX-2 inhibitors and concomittant use of 
misoprostol or PPI.3 Patients with moderate risk can be 
treated with either COX-2 or tradisional nonselective 
NSAID and misoprostol or PPI.3 Patients with low 
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risk, such as those who have no risk factor, can be 
treated with non-selective NSAID.3 Patients who are 
recommended with anti inflammatory analgetics and 
need low dose aspirin for cardiovascular disease should 
receive naproxen and misoprostol or PPI.
Moderate risk gastrointestinal patients with high 
cardiovascular risk should be treated with naproxen and 
misoprostol or PPI. Patients with high gastrointestinal 
and cardiovascular risk should avoid the use of NSAID 
or coxibs. Alternative treatments should be preacribed. 
All patients, regardless of their risks, who initiate long 
term NSAID traditional therapy should be considered 
for H. pylori test and be treated if it is positive.3
Gastroesophageal Reflux Therapy
Many studies have documented the significant 
effication of PPI in controlling GERD and treating 
esophagitis. A comparative study revealed the benefits 
of PPI over H2 antagonist. The recommended dose of 
PPI given before breakfast reduced the symptoms of 
and treated esophagitis in 85-90% patients.9
Empirical PPI therapy test is performed using 
double dose PPI for 1-2 weeks in patients presumably 
having GERD without further investigations using 
endoscopic examination. Test will be considered 
positive if more than 75% symptoms receeded after 
one week of therapy.9
At least 10-15% of GERD patients had suboptimal 
response against PPI especially those with advanced 
stage esophagitis. The reason for these failures remain 
unclear, however, they are associated with suboptimal 
treatments. Polymorphisms in Cytochrome P450 2C19 
genes (CYP2C19) which coded cytochrome P450 
isoenzymes that metabolized different PPI preparations 
are common in Asia and other populations.10 
Genetic mutation may cause someone become slow 
metabolizer and prolong the antisecretory effects of 
PPI. Acid inhibitory duration will decrease in fast 
metabolizers, and difference of PPI metabolism will 
result in incomplete acid secretion inhibition and high 
prevalence of GERD symptoms relapse at night.
History of PPI consumption is necessary in 
individuals who responded poorly against PPI. The 
optimum time to consume it is soon before breakfast. 
With proper time of consumption, the second dose 
taken before dinner would be helpful.10
New PPI product with longer biological half-time 
is now being developed. This prodrug is changed 
into an active sulphonamide by acids in the secretory 
canaliculi.11 Substitution of benzimidazole with 
imidazopyridine reduces the rate of metabolism, 
increases plasma and biological half-time from 60-90 
minutes to 9.3 hours.11 The benefits of this preparation 
need careful examination.
Maintenance Therapy
Most GERD patients, especially those who have 
grade III and IV esophagitis, will suffer a relapse 
when the treatment is stopped. A study of maintenance 
therapy compared ranitidine, cisapride, ranitidine and 
cisapride, omeprazole, and omeprazole with cisapride. 
All patients suffered from esophagitis upon preliminary 
endoscopy and were treated with omeprazole 40 mg 
daily for 8 weeks prior to taking any of maintenance 
regimens. After 12 months of therapy, remission state 
was maintained in 80-90% of the omeprazole group, 
compared to 49-60% in other groups. This study 
showed the superiority of PPI in maintaining remission 
and similar effective prophylactic dose as compared to 
that of early recovery.11 
Complication of GERD
PPI is effective in treating complications of 
GERD. In esophageal stricture, PPI decreases 
esophageal dilatation which is needed to overcome 
dysphagia more effective compared to H2 antagonist. 
In Barrett's esophagus, PPI is commonly used in 
Barrett's metaplasia patient, although there has been 
no study which show the regression of Barrett's 
esophagus or decrease risk of esophageal malignancy 
with pharmacological or surgical therapy. The dose 
of PPI is the same with the dose to cure esophagitis 
without metaplasia. Barrett's metaplasia patients 
need continuous surveillance for the development of 
dysplasia or adenocarcinoma.11 
SIDE EFFECTS AND LONG TERM SAFETY 
Three things need to be noted regarding safety of 
long term PPI, including prolonged hypergastrinemia, 
possible association of PPI and gaster atrophy, and 
chronic hypochlorhydria effect.12-17
PPI and Hip Fracture
Possibility of increased risk of fracture provoked 
US Food and Drugs Administrations (FDA) to 
recommend health services which prescribe PPI need to 
the consider lower dose which can overcome patients' 
condition adequately. Results of clinical studies on PPI 
treatment associated to increased risk of fracture are 
still controversial.5 
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A systematic review and meta-analysis on 
observational study revealed association between 
the use of PPI and increased risk of hip fracture 
(95% CI = 1.14-1.37; OR = 1,25) and vertebra (95% 
CI = 1.32-1.72; OR = 1,50), but there is no evidence 
in the duration effect in the subgroup analysis. 
Nevertheless, observational study cannot clarify if 
this is causal relationship or results from confounding 
factors. Randomized control trials are needed to prove 
or deny this result.5
PPI and Clostridium difficile Infection
There has been no conclusive evident showing that 
PPI can increase disease risk associated to Clostridium 
difficile (C. difficile). C. difficile is an anaerobic 
organism with spores. Acid fast spore is assumed to 
be the main vector in disease transmission. Although 
spore may survive in alkali environment, there is 
scarce epidemiology evident connecting the use of 
PPI with C. difficile infection. Although the role of 
gastric acidity maintain sterile environment in upper 
gastrointestinal tract, other significant effects in other 
intestinal infection which has not been detected.18
PPI and Vitamin also Iron
PPI very strongly inhibits gastric acid secretion, 
increases intragastric pH, and decreases hydrogen ion 
concentration several hundreds or thousands fold. As a 
consequence, PPI has the potency to influence essential 
micronutrient, such as: vitamin C, vitamin B12, and 
iron when it passes gaster, disrupts its activity in the 
gastric lumen and also its bioavailability.6 Nonetheless, 
concerns regarding long term effects of PPI in iron 
and vitamin B12 absorption each effect is usually 
mild, not clinically significant, and is overcomed by 
supplementation therapy.6
PPI and Food Allergy
PPI plays role in increasing allergy reactivation in 
patients with acid suppression treatment. PPI plays role 
in food allergy which is mediated by immunoglobulin 
E. Acid suppression treatment increases gastric pH into 
around 5. The optimum pH for pepsin in the gaster is 
1.8-3.2. Therefore, acid suppression disturbed pepsin 
enzymatic activity in digesting protein. When food 
protein is not degraded in gaster, the protein structures 
are maintained, therefore IgE antibody to food appears.19
PPI and Pneumonia
PPI creates hypochlorhydria or achlorhydria in 
gastrointestinal tract, thus ingested pathogen survives 
while actually should be killed by the actual gastric pH. 
Regurgitation of ingested bacteria to the oropharyng 
may induce respiratory tract infection.
Studies showed the increased risk of pneumonia 
associated with PPI administration. Several studies 
stated that this association is due to the underlying 
confounding condition, which is GERD, and not the 
PPI administration itself. Patients with severe reflux 
may have more risk of aspiration and experience 
pneumonia not only because they use acid suppression 
treatment. Further study is needed to evaluate the 
relationship of pneumonia and PPI treatment.20 
PPI and Acute Interstitial Nephritis
Several case reports and literature reviews showed 
that PPI was associated with acute interstitial nephritis 
(AIN). AIN cases are considered to be related with PPI 
if medical records revealed that PPI is the only change 
in the treatment before the diagnosis of AIN. From 28 
identified cases of AIN, 18 (64%) is associated with the 
use of PPI (omeprazole, pantoprazole, esomeprazole, 
or rabeprazole). The median age of patients was 74, 
median of PPI use was 11 weeks. The presenting signs 
were unspecific, including 39% patients complained 
of fatigue, 39% nausea, 22% weight loss. The most 
common abnormal findings in urinalysis include 
pyuria (72%), proteinuria (67%), and eosinophiluria 
(61%). Normocytic normochrome anemia is found in 
89% cases and C-reactive protein is increased in 78% 
cases. Kidney biopsy showed interstitial eosinophillia 
in 83% cases.21
During 3 months of AIN diagnosis and PPI cesation, 
mostly patients' kidney function recovers. Calculation 
of glomerulus filtration rate is lower compared to the 
start in 3 months and 6 months. No AIN predictor data 
linked to PPI.21
AIN associated PPI is an idosyncratic reaction 
without predictable risk factor. The pathogenesis is 
unclear, but may appear due to hypersensitivity reaction 
towards drugs or their metabolites. This metabolite 
may function as a hapten and resemble kidney antigen, 
or they gather into immune complex which circulates. 
Drug induced AIN is treated with corticosteroid, for 
example in this study all patients received prednisone 
50-70 mg per day for 8-12 weeks, but this approach 
has not been evaluated with randomized controlled 
trial (RCT). Most patients with drug induced AIN will 
experience kidney function recovery, some will remain 
to experience kidney function disturbance, and some 
develop into terminal stage of chronic kidney disease. 
Considering that drug induced AIN has reversible 
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potency, the important key to prevent its development 
is by recognition and diagnosis. If PPI treatment is 
given, patients need to be followed and sought for 
nonspecific complains which has potency to be related 
with the various manifestation of PPI related AIN.2
Proton Pump Inhibitor and Clopidogrel
Food and drug administration (FDA) stated that the 
combined use of omeprazole and clopidogrel should 
be avoided because effect in the level of clopidogrel 
active metabolite and anti coagulation activity. 
Considering the inhibitory level between various PPI, 
it is still unknown other PPI which disrupts clopidogrel. 
Esomeprazole is an omeprazole containing PPI 
which inhibit CYP2C19 and also need to be avoided 
combination with clopidogrel.25
However, large scale randomized trial on omeprazole 
vs. placebo in the use of clopidogrel revealed no 
significant difference in cardiovascular events (95% 
CI = 0.68-1.44; HR = 0.99) along with the significant 
decrease of gastrointestinal event (95% CI = 0.18-0.63; 
HR = 0.34).26
CONCLUSION
PPI is the strongest available gastric acid secretion 
inhibitor. PPI is effective to manage all acid related 
disorders, including peptic ulcer, gastroesofageal reflux 
disease, NSAIDs gastropathy, and Zollinger-Ellison 
syndrome. Several studies compared various PPI. 
Although some differences have been reported, there 
is only small difference and the clinical significance 
is unclear.
PPI is probably associated with diarrhea due to 
Clostridium difficile, pneumonia, hip fracture, vitamin 
B12 deficiency, and IgE mediated allergic reaction. 
Several studies showed strong relationship, but had 
limitations in study design and size. Further research 
is needed to know the real association between PPI 
and its various side effects.
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